The incidental monoclonal protein: Current approach to management of monoclonal gammopathy of undetermined significance (MGUS)

Blood Reviews

Volumn 23, Issue 6, 2009, Pages 257-265

  Madan, Sumit ^a   Greipp, Philip R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Immunoglobulins; Monoclonal gammopathy; Smoldering multiple myeloma

Indexed keywords

IMMUNOGLOBULIN; M PROTEIN;

AMYLOIDOSIS; ARTICLE; BONE LESION; BONE MARROW CELL; CELL PROLIFERATION; CLINICAL PROTOCOL; DISEASE COURSE; FOLLOW UP; FRACTURE; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; MALIGNANT TRANSFORMATION; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OSSIFICATION; OSTEOLYSIS; PATHOGENESIS; PLASMA CELL; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

GLYCOPROTEINS; HUMANS; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; RISK FACTORS;

EID: 70349973711     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2009.07.004     Document Type: Article

References (128)

1. Dispenzieri A., Gertz M.A., Therneau T.M., and Kyle R.A. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc 76 (2001) 476-487
2. Kyle R.A. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 64 (1978) 814-826
3. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New Engl J Med 346 (2002) 564-569
4. Criteria for the classification of monoclonal gammopathies. Multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121 (2003) 749-757
5. Rajkumar S.V., Lacy M.Q., and Kyle R.A. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev 21 (2007) 255-265
6. Rajkumar S.V., Dispenzieri A., and Kyle R.A. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 81 (2006) 693-703
7. Kyle R.A., Remstein E.D., Therneau T.M., et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. New Engl J Med 356 (2007) 2582-2590
8. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Prevalence of monoclonal gammopathy of undetermined significance. New Engl J Med 354 (2006) 1362-1369
9. Iwanaga M., Tagawa M., Tsukasaki K., Kamihira S., and Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance. study of 52, 802 persons in Nagasaki City, Japan. Mayo Clin Proc 82 (2007) 1474-1479
10. Kyle R.A., Finkelstein S., Elveback L.R., and Kurland L.T. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 40 (1972) 719-724
11. Saleun J.P., Vicariot M., Deroff P., and Morin J.F. Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol 35 (1982) 63-68
12. Axelsson U., Bachmann R., and Hallen J. Frequency of pathological proteins (M-components) om 6, 995 sera from an adult population. Acta Med Scand 179 (1966) 235-247
13. Giraldo M.P., Rubio-Felix D., Perella M., Gracia J.A., Bergua J.M., and Giralt M. Monoclonal gammopathies of undetermined significance. Clinical course and biological aspects of 397 cases. Sangre (Barc) 36 (1991) 377-382
14. Landgren O., Gridley G., Turesson I., et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107 (2006) 904-906
15. Cohen H.J., Crawford J., Rao M.K., Pieper C.F., and Currie M.S. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 104 (1998) 439-444
16. Munshi N.C. Monoclonal gammopathy of undetermined significance. genetic vs. environmental etiologies. Mayo Clin Proc 82 (2007) 1457-1459
17. Blade J. Clinical practice. Monoclonal gammopathy of undetermined significance. New Engl J Med 355 (2006) 2765-2770
18. Kyle R.A., and Rajkumar S.V. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am 21 (2007) 1093-1113 ix
19. Landgren O., Katzmann J.A., Hsing A.W., et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 82 (2007) 1468-1473
20. Brown L.M., Linet M.S., Greenberg R.S., et al. Multiple myeloma and family history of cancer among blacks and whites in the US. Cancer 85 (1999) 2385-2390
21. Eriksson M., and Hallberg B. Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study. Cancer Causes Control 3 (1992) 63-67
22. Landgren O., Linet M.S., McMaster M.L., Gridley G., Hemminki K., and Goldin L.R. Familial characteristics of autoimmune and hematologic disorders in 8, 406 multiple myeloma patients: a population-based case-control study. Int J Cancer 118 (2006) 3095-3098
23. Ogmundsdottir H.M., Haraldsdottirm V., Johannesson G.M., et al. Familiarity of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families. Haematologica 90 (2005) 66-71
24. Vachon C.M., Kyle R.A., Therneau T.M., et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 114 (2009) 785-790
25. Brown L.M., Gridley G., Check D., and Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111 (2008) 3388-3394
26. Linet M.S., McLaughlin J.K., Harlow S.D., and Fraumeni J.F. Family history of autoimmune disorders and cancer in multiple myeloma. Int J Epidemiol 17 (1988) 512-513
27. Hsing A.W., Hansson L.E., McLaughlin J.K., et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 71 (1993) 745-750
28. Brinton L.A., Gridley G., Hrubec Z., Hoover R., and Fraumeni Jr. J.F. Cancer risk following pernicious anaemia. Br J Cancer 59 (1989) 810-813
29. Landgren O., Kyle R.A., Hoppin J.A., et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood 113 (2009) 6386-6391
30. Bergsagel P.L., and Kuehl W.M. The molecular biology of multiple myeloma. In: Malpas J.S., Bergsagel D.E., Kyle R.A., and Anderson K.C. (Eds). Myeloma: Biology and Management. 3rd ed. (2004), Saunders, Philadelphia 35-58
31. Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64 (2004) 1546-1558
32. Blade J., Rosinol L., Cibeira M.T., and de Larrea C.F. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 22 (2008) 1651-1657
33. Brousseau M., Leleu X., Gerard J., et al. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients. Clin Cancer Res 13 (2007) 6026-6031
34. Avet-Loiseau H., Li J.Y., Facon T., et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 58 (1998) 5640-5645
35. Nishida K., Tamura A., Nakazawa N., et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90 (1997) 526-534
36. Avet-Loiseau H., Facon T., Daviet A., et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 59 (1999) 4546-4550
37. Fonseca R., Bailey R.J., Ahmann G.J., et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100 (2002) 1417-1424
38. Chng W.J., Van Wier S.A., Ahmann G.J., et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 106 (2005) 2156-2161
39. Konigsberg R., Ackermann J., Kaufmann H., et al. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia 14 (2000) 1975-1979
40. Ackermann J., Meidlinger P., Zojer N., et al. Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance. Br J Haematol 103 (1998) 1161-1163
41. Corradini P., Inghirami G., Astolfi M., et al. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 8 (1994) 758-767
42. Drach J., Ackermann J., Fritz E., et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92 (1998) 802-809
43. Harada H., Kawano M.M., Huang N., et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81 (1993) 2658-2663
44. Ocqueteau M., Orfao A., Almeida J., et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 152 (1998) 1655-1665
45. Kumar S., Rajkumar S.V., Kimlinger T., Greipp P.R., and Witzig T.E. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia 19 (2005) 1466-1470
46. Vacca A., Ribatti D., Roncali L., and Dammacco F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk Lymphoma 20 (1995) 27-38
47. Vacca A., Ribatti D., Roncali L., et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87 (1994) 503-508
48. Aguayo A., Kantarjian H., Manshouri T., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96 (2000) 2240-2245
49. Rajkumar S.V., Mesa R.A., Fonseca R., et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 8 (2002) 2210-2216
50. Kumar S., Witzig T.E., Timm M., et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 104 (2004) 1159-1165
51. Vacca A., Ribatti D., Presta M., et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93 (1999) 3064-3073
52. van de Donk N.W., Lokhorst H.M., and Bloem A.C. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 19 (2005) 2177-2185
53. Kawano M., Hirano T., Matsuda T., et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332 (1988) 83-85
54. Ogata A., and Anderson K.C. Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth. Leuk Res 20 (1996) 303-307
55. Rawstron A.C., Fenton J.A., Ashcroft J., et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 96 (2000) 3880-3886
56. Lust J.A., and Donovan K.A. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 13 (1999) 1117-1125
57. Hideshima T., Chauhan D., Schlossman R., Richardson P., and Anderson K.C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20 (2001) 4519-4527
58. Kuehl W.M., and Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2 (2002) 175-187
59. Hanamura I., Stewart J.P., Huang Y., et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108 (2006) 1724-1732
60. Liu P., Leong T., Quam L., et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 88 (1996) 2699-2706
61. Bezieau S., Devilder M.C., Avet-Loiseau H., et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 18 (2001) 212-224
62. Corradini P., Ladetto M., Voena C., et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood 81 (1993) 2708-2713
63. Blade J., Lopez-Guillermo A., Rozman C., et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 81 (1992) 391-394
64. Gregersen H., Mellemkjaer L., Ibsen J.S., Dahlerup J.F., Thomassen L., and Sorensen H.T. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica 86 (2001) 1172-1179
65. Cesana C., Klersy C., Barbarano L., et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 20 (2002) 1625-1634
66. Rosinol L., Cibeira M.T., Montoto S., et al. Monoclonal gammopathy of undetermined significance. predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc 82 (2007) 428-434
67. Baldini L., Guffanti A., Cesana B.M., et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 87 (1996) 912-918
68. Kyle R.A., Therneau T.M., Rajkumar S.V., Larson D.R., Plevak M.F., and Melton III L.J. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance. the original Mayo Clinic series 25 years later. Mayo Clin Proc 79 (2004) 859-866
69. Kyle R.A. "Benign" monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clin Proc 68 (1993) 26-36
70. Rajkumar S.V., Kyle R.A., Therneau T.M., et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol 127 (2004) 308-310
71. Rajkumar S.V., Kyle R.A., Therneau T.M., et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106 (2005) 812-817
72. Katzmann J.A., Clark R.J., Abraham R.S., et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48 (2002) 1437-1444
73. Witzig T.E., Gertz M.A., Lust J.A., Kyle R.A., O'Fallon W.M., and Greipp P.R. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 88 (1996) 1780-1787
74. Kumar S., Rajkumar S.V., Kyle R.A., et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 23 (2005) 5668-5674
75. Kyle R.A. 'Benign' monoclonal gammopathy. A misnomer?. JAMA 251 (1984) 1849-1854
76. Montoto S., Blade J., and Montserrat E. Monoclonal gammopathy of undetermined significance. New Engl J Med 346 (2002) 2087-2088 (author reply 2087-2088)
77. Blade J. On the "significance" of monoclonal gammopathy of undetermined significance. Mayo Clin Proc 79 (2004) 855-856
78. Terpos E., Szydlo R., Apperley J.F., et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102 (2003) 1064-1069
79. Politou M., Terpos E., Anagnostopoulos A., et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 126 (2004) 686-689
80. Lust J.A., and Donovan K.A. Biology of the transition of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma. Cancer Control 5 (1998) 209-217
81. Rajkumar S.V. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management hematology. Am Soc Hematol Educ Program (2005) 340-345
82. Pecherstorfer M., Seibel M.J., Woitge H.W., et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance. quantification by urinary pyridinium cross-links of collagen. Blood 90 (1997) 3743-3750
83. Vejlgaard T., Abildgaard N., Jans H., Nielsen J.L., and Heickendorff L. Abnormal bone turnover in monoclonal gammopathy of undetermined significance. analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens. Eur J Haematol 58 (1997) 104-108
84. Gregersen H., Jensen P., Gislum M., Jorgensen B., Sorensen H.T., and Norgaard M. Fracture risk in patients with monoclonal gammopathy of undetermined significance. Br J Haematol 135 (2006) 62-67
85. Jakob C., Zavrski I., Heider U., et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol 69 (2002) 37-42
86. Hernandez J.M., Suquia B., Queizan J.A., et al. Bone remodelation markers are useful in the management of monoclonal gammopathies. Hematol J 5 (2004) 480-488
87. Laroche M., Attal M., and Dromer C. Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma. Clin Rheumatol 15 (1996) 347-352
88. Diamond T., Levy S., Smith A., Day P., and Manoharan A. Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Intern Med J 31 (2001) 272-278
89. Melton III L.J., Rajkumar S.V., Khosla S., Achenbach S.J., Oberg A.L., and Kyle R.A. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 19 (2004) 25-30
90. Pepe J., Petrucci M.T., Nofroni I., et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol 134 (2006) 485-490
91. Golombick T., and Diamond T. Prevalence of monoclonal gammopathy of undetermined significance/myeloma in patients with acute osteoporotic vertebral fractures. Acta Haematol 120 (2008) 87-90
92. Pongchaiyakul C., Nguyen N.D., Jones G., Center J.R., Eisman J.A., and Nguyen T.V. Asymptomatic vertebral deformity as a major risk factor for subsequent fractures and mortality: a long-term prospective study. J Bone Miner Res 20 (2005) 1349-1355
93. Pepe J., Petrucci M.T., Mascia M.L., et al. The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance. Calcif Tissue Int 82 (2008) 418-426
94. Berenson J.R., Yellin O., Boccia R.V., et al. Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin Cancer Res 14 (2008) 6289-6295
95. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
96. Kristinsson S.Y., Fears T.R., Gridley G., et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 112 (2008) 3582-3586
97. Srkalovic G., Cameron M.G., Rybicki L., Deitcher S.R., Kattke-Marchant K., and Hussein M.A. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101 (2004) 558-566
98. Sallah S., Husain A., Wan J., Vos P., and Nguyen N.P. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 15 (2004) 1490-1494
99. Auwerda J.J., Sonneveld P., de Maat M.P., and Leebeek F.W. Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders. Clin Lymphoma Myeloma 7 (2007) 462-466
100. Dispenzieri A. POEMS syndrome. Blood Rev 21 (2007) 285-299
101. Dispenzieri A., Kyle R.A., Lacy M.Q., et al. POEMS syndrome: definitions and long-term outcome. Blood 101 (2003) 2496-2506
102. James K., Fudenberg H., Epstein W.L., and Shuster J. Studies on a unique diagnostic serum globulin in papular mucinosis (lichen myxedematosus). Clin Exp Immunol 2 (1967) 153-166
103. Powell F.C., Greipp P.R., and Su W.P. Discoid lupus erythematosus and monoclonal gammopathy. Br J Dermatol 109 (1983) 355-360
104. Kyle R.A., and Rajkumar S.V. Monoclonal gammopathy of undetermined significance. Br J Haematol 134 (2006) 573-589
105. Pomann J.J., and Rudner E.J. Scleromyxedema revisited. Int J Dermatol 42 (2003) 31-35
106. Kovary P.M., Dhonau H., and Happle R. Paraproteinaemia in erythema elevatum diutinum. Arch Dermatol Res 260 (1977) 155-158
107. Chowdhury M.M., Inaloz H.S., Motley R.J., and Knight A.G. Erythema elevatum diutinum and IgA paraproteinaemia: 'a preclinical iceberg'. Int J Dermatol 41 (2002) 368-370
108. Zent C.S., Wilson C.S., Tricot G., et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 91 (1998) 3518-3523
109. Badley A.D., Portela D.F., Patel R., et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl Surg 2 (1996) 375-382
110. Gosselin S., Kyle R.A., and Dyck P.J. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol 30 (1991) 54-61
111. Dingli D., Larson D.R., Plevak M.F., Grande J.P., and Kyle R.A. Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. Am J Kidney Dis 46 (2005) 278-282
112. Czarnecki P.G., Lager D.J., Leung N., Dispenzieri A., Cosio F.G., and Fervenza F.C. Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. Kidney Int 75 (2009) 420-427
113. Esparza A.R., Chazan J.A., Nayak R.N., and Cavallo T. Fibrillary (immunotactoid) glomerulopathy. A possible role for kappa light chain in its etiology and/or pathogenesis. Am J Surg Pathol 15 (1991) 632-643
114. Rollino C., Coppo R., Mazzucco G., et al. Monoclonal gammopathy and glomerulonephritis with organized microtubular deposits. Am J Kidney Dis 15 (1990) 276-280
115. Malik A.A., Ganti A.K., Potti A., Levitt R., and Hanley J.F. Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am J Gastroenterol 97 (2002) 1371-1374
116. Rajkumar S.V., Kyle R.A., Plevak M.F., Murray J.A., and Therneau T.M. Helicobacter pylori infection and monoclonal gammopathy of undetermined significance. Br J Haematol 119 (2002) 706-708
117. Alexanian R. Monoclonal gammopathy in lymphoma. Arch Intern Med 135 (1975) 62-66
118. Kyle R.A., and Garton J.P. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 62 (1987) 719-731
119. Noel P., and Kyle R.A. Monoclonal proteins in chronic lymphocytic leukemia. Am J Clin Pathol 87 (1987) 385-388
120. Zawadzki Z.A., and Benedek T.G. Rheumatoid arthritis, dysproteinemic arthropathy, and paraproteinemia. Arthritis Rheum 12 (1969) 555-568
121. Renier G., Renier J.C., Gardembas-Pain M., Chevailler A., Boasson M., and Hurez D. Ankylosing spondylitis and monoclonal gammopathies. Ann Rheum Dis 51 (1992) 951-954
122. Ilfeld D., Barzilay J., Vana D., Ben-Bassat M., Joshua H., and Pick I. IgG monoclonal gammopathy in four patients with polymyalgia rheumatica. Ann Rheum Dis 44 (1985) 501
123. Porcel J.M., Ordi J., Tolosa C., Selva A., Castro-Salomo A., and Vilardell M. Monoclonal gammopathy in systemic lupus erythematosus. Lupus 1 (1992) 263-264
124. Mussini C., Ghini M., and Mascia M.T. Et al. HCV and monoclonal gammopathies. Clin Exp Rheumatol 13 Suppl. 13 (1995) S45-49
125. Pascual M., Widmann J.J., and Schifferli J.A. Recurrent febrile panniculitis and hepatitis in two patients with acquired complement deficiency and paraproteinemia. Am J Med 83 (1987) 959-962
126. Droder R.M., Kyle R.A., and Greipp P.R. Control of systemic capillary leak syndrome with aminophylline and terbutaline. Am J Med 92 (1992) 523-526
127. Lamboley V., Zabraniecki L., Sie P., Pourrat J., and Fournie B. Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a literature review. Joint Bone Spine 69 (2002) 62-67
128. Fremeaux-Bacchi V., Guinnepain M.T., Cacoub P., et al. Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2. Am J Med 113 (2002) 194-199